ABSTRACT
Trade name: Desyrel (Apothecon) Other common trade names: Alti-Trazodone; Bimaran; Deprax; Desirel; Molipaxin;
Sideril; Taxagon; Trazalon Indications: Depression Category: Heterocyciic antidepressant Half-life: 3-6 hours Clinically important, potentially hazardous interactions with: citalopram,
fluoxetine, fluvoxamine, linezolid, nefazodone, paroxetine, sertraline, venlafaxine
Reactions
Skin Angioedema
(2001): Adson DE+, Ann Pharmacother 35(11), 1375 Diaphoresis (>1%) Edema (1-10%)
Erythema multiforme (1985): Ford HE+, J Clin Psychiatry 46, 294 Exanthems (1988): Warnock JK+, Am J Psychiatry 145, 425 (1986): Rongioletti F+, J Am Acad Dermatol 14, 274 (1984): Cohen LE, J Am Acad Dermatol 10, 303 (1984): Cohen LE, J Am Acad Dermatol 11, 526 (1980): AI-Yassiri MM+, Neuropharmacology 19, 1191 (1979): Trapp GA+, Psychopharmacol Bull 15, 25 Exfoliative dermatitis (1983): Chu AG+, Ann Intern Med 99, 128 Formication (1987): Peabody CA, J Clin Psychiatry 48, 385 Photosensitivity (1994): Berger TG+, Arch Dermatol 130, 609 (in HIV-infected) (1986): Rongioletti F+, J Am Acad Dermatol 14, 274 Pruritus (<1%) Psoriasis (exacerbation) (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
197 (passim) (1986): Barth JH+, Br J Dermatol 115, 629 (generalized and pustular) Purpura Rash (sic) (<1%) (1985): Longstreth GF+, J Am Acad Dermatol 13, 149 Urticaria (1988): Warnock JK+, Am J Psychiatry 145, 425 (1984): Cohen LE, J Am Acad Dermatol 10, 303 (1983): Fabre LF+, J Clin Psychiatry 44, 17 Vasculitis (1984): Mann SC+, J Am Acad Dermatol 10, 669
Hair Hair-alopecia
(2000): Mercke Y+, Ann Clin Psychiatry 12, 35 (1988): Warnock JK+, Am J Psychiatry 145, 425
Nails Nails-leukonychia
(1985): Longstreth GF+, J Am Acad Dermatol 13, 149
Other Dysgeusia (>10%)
Galactorrhea Gynecomastia Headache Hypersensitivity
Myalgia (1-10%) Paresthesias (>1%) Parkinsonism (2002): Fukunishi I+, Nephron 90(2), 222 Priapism (2001): Warner MD+, Pharmacopsychiatry 34(4), 128 (12%) (2000): Correas Gomez MA+, Actas Urol Esp (Spanish) 24(10), 840 (1998): Myrick H+, Ann Clin Psychiatry 10, 81 (1994): Thavundayil JX+, Neuropsychobiology 30, 4 (1993): Pescatori ES+, J Urol 149, 1557 Priapism (clitoral) (2002): Kem DL+, J Am Acad Child Adolesc Psychiatry 41(7), 758 (2002): Medina CA, Obstet Gynecol 100(5 Pt 2), 1089 (clitoral) Serotonin syndrome (2001): Adson DE+, Ann Pharmacother 35(11), 1375 (2001): McCue RE+, Am J Psychiatry 158(12), 2088 Sialorrhea Tremor (1-10%) Xerostomia (>10%) (1982): Rawls WN, Drug Intell Clin Pharm 16, 7
Trade name: Remodulin (United Therapeutics) Indications: Pulmonary hypertension Category: Prostacyclin analog; Vasodilator Half-life: 2-4 hours Clinically important, potentially hazardous interactions with: anticoagulants
Reactions
Skin Diaphoresis
Edema (9%) Erythema Flushing Penpheral edema Pruritus (8%) Rash (sic) (14%)
Other
Dizziness (9%) Injection-site bleeding (33%) Injection-site induration Injection-site pain (85%) (2002): Simonneau G+, Am J Respir Crit Care Md 165(6), 800 (2002): Vachiery JL+, Chest 121(5), 1561 Injection-site reactions (83%) Pain (13%) Pharyngitis (12%)
Synonym: All-trans-retinoic acid Trade names: Aberela; Acnavit; Aknemycin Plus (Hermal); ATRA; Atragen; Avita
(Bertek); Avitoin; Dermojuventus; Relief; Renova (Ortho); Retin-A Micro (Ortho); Retinoic Acid; Retinova; SolagJJ (Bristol-Myers Squibb); SteiVAA; Tri-Luma (Galderma); Vesanoid (Roche)
Other common trade names: A-Acido; Aberal; Acid A Vit; Acta; Airol; Alquingel; Alten; Avitcid; Cordes VAS; Derm A; Dermairol; Epi-Aberel; Eudyna; Stieva-A; Vitamin A Acid
Indications: Acne vulgaris, skin aging, facial roughness, fine wrinkles, hyperpigmentation [T], acute promyelocytic leukemia (APL) [O]
Category: Retinoid Half-life: 0.5-2 hours Clinically important, potentially hazardous interactions with: aldesleukin,
bexarotene Note: [T]=Topical, [O]=Oral
Reactions
Skin Acne (1%)
(1996): Shalita A+, J Am Acad Dermatol 34, 482 Acute febrile neutrophilic dermatosis (Sweet’s syndrome) (1999): Takada S+, Int J Hematol 70(1), 26 (1997): Hatake K+, Int J Hematol 66(1), 13 (1996): Christ E+, Leukemia 10(4), 731 Bullous eruption (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 Burning (10-40%) ([O] [T])
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41 (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1997): Gilchrest B, J Am Acad Dermatol 36, S27-36 (1997): Drug Information Handbook Fifth Ed., American Pharmaceutical Association,
Hudson, OH (1996): Shalita A+, J Am Acad Dermatol 34, 482 (1996): Shroot B, Presented at Dermatology Update ’95 (Montreal, Canada) (1995): Hall R, Inpharma December, 13 (1995): Package Insert Hoffman-LaRoche, Inc. (Nutley, NJ) (1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638 (1988): Cohen BA+, Pediatric Dermatology 1, New York: Churchill Livingstone, 663 (1977): Muller SA+, Arch Dermatol 113(8), 1052 Carcinoma ([O]) Cellulitis (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed., American Pharmaceutical Association
(Hudson, OH) (1995): Gillis JC+, Drugs 50(5), 897 (1995): Package insert Hoffman-LaRoche, Inc. (Nutley, NJ) Cheilitis (10%) ([O]) (1997): Drug Information Handbook Fifth Ed. (American Pharmaceutical Association,
Hudson, OH) (1995): Package insert (Hoffman-LaRoche, Inc., Nutley, NJ) Crusting (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 Dermatitis (sic) (1997): Gilchrest B, J Am Acad Dermatol 36, S27-36 (1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638 Desquamation (14%) Diaphoresis (20%) Dry skin (49-100%) ([O]) (1998): Soignet SL+, Leukema 12(10), 1518 (1995): Dockx P+, Br J Dermatol 133(3), 426 (1995): Gillis JC+, Drugs 50(5), 897 (1992): Fenaux P+, Blood 80(9), 2176 (1991): Chen ZX+, Blood 78(6), 1413 (1988): Huang ME+, Blood 72(2), 567
Edema (29%) ([O]) (1997): Drug Information Handbook Fifth Ed. (American Pharmaceutical Association,
Hudson, OH) (1995): Package insert (Hoffman-LaRoche, Inc., Nutley, NJ) Erythema (1-49%) ([O] [T]) (2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (2000): Kreusch+, Curr Med Res & Opinion 16(1), 1 (1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41 (1998): Webster GF, J Am Acad Dermatol 39(2), S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36(6), S126-34 (1997): Gilchrest BA, J Am Acad Dermatol 36(3), S27-36 (1997): Drug Information Handbook Fifth Ed (American Pharaceutical Association,
Hudson, OH) (1996): Shalita A+, J Am Acad Dermatol 34(3), 482 (1996): Shroot B, Presented at Dermatology Update ’95, Montreal, Canada (1995): Hall R, Inpharma December, 13 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (1992): Olsen EA+, J Am Acad Dermatol 26(2), 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638 (1988): Cohen BA+, Pediatric Dermatology 1. New York: Churchill Livingstone, 663 (1977): Muller SA+, Arch Dermatol 113(8), 1052 Erythema nodosum Exfoliation (8.3%) ([O]) (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1988): Huang ME+, Blood 72(2), 567 Facial edema (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley NJ Flaking (23%) ([O]) Flushing (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1996): Miller VA+, Clin Cancer Res 2(3), 471 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Hyperkeratosis (78%) ([O]) (1991): Chen ZX+, Blood 78, 1413 Hypopigmentation (5%) (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 Infections (sic) (58%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc,. Nutley, NJ (1991): Chen ZX+, Blood 78(6), 1413 Irritation (sic) (5%) (2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (1998): Cohen BA+, Pediatric Dermatology 1, New York: Churchill Livingstone, 663 (1997): Clucas A+, J Am Acad Dermatol 36, S116-8 (1996): Shalita A+, J Am Acad Dermatol 34(3), 482 Localized edema (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1997): Gilchrest BA, J Am Acad Dermatol 36, S27-36 (1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638 Ocular pruritus (10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Natley, NJ Pallor (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Palmar-plantar peeling (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Photosensitivity (10%) ([O] [T]) (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Pigmentation (5%) (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 Pruritus (10-40%) ([O] [T]) (2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (2000): Kreusch+, Curr Med Res & Opinion 16(1), 1 (1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41 (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH
(1996): Shalita A+, J Am Acad Dermatol 34, 482 (1995): Gillis JC+, Drugs 50(5), 897 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (1988): Cohen BA+, Pediatric Dermatology 1, New York: Churchill Livingstone, 663 (1977): Muller SA+, Arch Dermatol 113(8), 1052 Rash(sic) (54%) ([O] [T]) (1998): Webster GF, J Am Acad Dermatol 39, S38-44 (1997): Cunliffe WJ+, J Am Acad Dermatol 36, S126-34 (1997): Drug Information Handbook Fifth Ed American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (1991): Warrell RP+, N Engl J Med 324, 1385 Scaling (10-40%) (2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (2000): Kreusch+, Curr Med Res & Opinion 16(1), 1 (1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41 (1997): Gilchrest BA, J Am Acad Dermatol 36, S27-36 (1996): Shalita A+, J Am Acad Dermatol 34, 482 (1996): Shroot B, Presented ar Dermatology Update ’95 Montreal, Canada (1995): Hall R, Inpharma December, 13 (1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1988): Cohen BA+, Pediatric Dermatology I New York: Chrurchill Livingstone, 663 Shivering (63%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Stinging (1-26%) (1997): Gilchrest BA, J Am Acad Dermatol 36, S27-36 (1996): Shalita A+, J Am Acad Dermatol 34, 482 (1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, J Am Acad Dermatol 21, 645 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638 Sunburn (1%) (1996): Shalita A+, J Am Acad Dermatol 34, 482 Ulcerations (penile) (2000): Esser AC+, J Am Acad Dermatol 43(2 Pt 1), 316 (1995): Gillis JC+, Drugs 50, 897 Vesiculobullous eruption Xerosis (77%) (2000): Kreusch+, Curr Med Res & Opinion 16(1), 1 (1997): Gilchrest BA, J Am Acad Dermatol 36, S27 (1996): Shalita A+, J Am Acad Dermatol 34, 482
(1992): Olsen EA+, J Am Acad Dermatol 26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Leyden JJ+, J Am Acad Dermatol 21, 638
Hair Hair-alopecia areata (14%) ([O])
(1997): Drug Information Handbook Fifth Ed American Pharmaceutical Association, Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Other Arthralgia (10%) ([O])
(1997): Drug Information Handbook American Pharmaceutical Association, Hudson, OH
(1995): Gillis JC+, Drugs 50, 897 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Bone or joint pain (77%) ([O]) (1995): Gillis JC+, Drugs 50, 897 (1992): Fenaux P+, Blood 80, 2176 (1988): Huang ME+, Blood 72, 567 Conjunctivitis (<1%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Death ([O]) (1997): Fenaux P+, N Engl J 337, 1076 (1997): Larson RA+ In: Hall JB+, Prindples of Critical Care Second Ed. New York,
McGraw-Hill (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Depression (14%) ([O]) (1997): Drug Information Handbook Fifth Ed, American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Dry eyes (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Fever ([O]) (1997): Fenaux P+, N Engl J Med 337, 1076 (1997): Larson RA+ In: Halll JB+, Principles of Critical Care Second Ed., New York,
McGraw (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Gingivitis (<1%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
Headache Injection-site reactions (17%) Myalgia (14%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Myositis Ocular pigmentation (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Pain (37%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Paresthesias (17%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Phlebitis (11%) Pseudotumor cerebri (<1%) ([O]) (2003): Colucciello M, Arch Ophthalmol 121(7), 1064 (1997): Tallman MS+, N Engl J Med 337, 1021 (1996): Visani G+, Leuk Lymphoma 23(5-6), 437 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (1994): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1993): Mahmoud HH+, Lancet 342(8884), 1394 (1991): Warrell RP+, N Engl J Med 324, 1385 Retinoic Acid-APL (RA-APL) syndrome* (25%) ([O]) (1997): Fenaux P+, N Engl J Med 337, 1076 (1997): Sacchi S+, Haematologica 82(1), 106 (1997): Tallman MS+, N Engl J Med 337, 1021 (1995): Gillis JC+, Drugs 50, 897 (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ (1992): Fenaux P+, Blood 80, 2176 Tingling (26%) Tremor (1-10%) ([O]) (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ
*Note: The RA-APL syndrome is characterized by fever, dyspnea, weight gain, pulmonary infiltrates and pleural effusions. Some patients have expired due to multiorgan failure
Xerostomia (10%) ([O]) (1997): Drug Information Handbook Fifth Ed American Pharmaceutical Association,
Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc., Nutley, NJ Note: Oral tretinoin can cause birth defects, and women should avoid Tretinoin when
pregnant or trying to conceive. Avoid prolonged exposure to sunlight
Trade names: Dyazide (GSK); Dyrenium (Wellspring); Maxzide (Bertek) Other common trade names:Amterene; Diarrol; Diuteren; Dytac; Reviten; Suloton;
Trian Indications: Edema Category: Antihypertensive; Potassium-sparing antihypertensive diuretic Half-life: 1-2 hours Clinically important, potentially hazardous interactions with: ACE inhibitors,
benazepril, captopril, cyclosporine, enalapril, fosinopril, indomethacin, juniper, lisinopril, moexipril, potassium iodide, potassium salts, quinapril, ramipril, spironolactone, trandolapril
Dyazide is triamterene and hydrochlorothiazide*; Maxzide is triamterene and hydrochlorothiazide*
Reactions
Skin Chills
Diaphoresis (1979): Fan WJ+, Pediatrics 64, 698 Edema (1-10%) Exanthems Flushing (<1%) Lupus erythematosus (with hydrochlorothiazide) (1991): Wollenberg A+, Hautarzt (German) 42, 709 (1988): Darken M+, J Am Acad Dermatol 18, 38 Perleche Photosensitivity (1989): Rosen C, Semin Dermatol 8, 149 (1987): Fernandez de Corres L+, Contact Dermatitis 17, 114 Pruritus Purpura Rash (sic) (1-10%)
Urticaria Vasculitis
Other Anaphylactoid reactions
Dysgeusia (1999): Sorkin M, Denver, CO (from Internet) (observation) Glossitis Gynecomastia (<1%) Headache Paresthesias Pseudoporphyria (1990): Motley RJ, BMJ 300, 1468 Stomatodynia (1999): Sorkin M, Denver, CO (from Internet) (observation) Xerostomia (1987): Fernandez de Corres L+, Contact Dermatitis 17, 114
*Note: Hydrochlorothiazide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome
Trade name: Halcion (Pharmacia) Other common trade names: Dumozolam; Novo-Triolam; Nu-Triazo; Nuctane;
Somese; Somniton; Songar; Trialam Indications: Insomnia Category: Benzodiazepine sedative-hypnotic Half-life: 1.5-5.5 hours Clinically important, potentially hazardous interactions with: atazanavir,
clarithromycin, delavirdine, efavirenz, erythromycin, indinavir, itraconazole, ketoconazole, rifampin, ritonavir
Reactions
Skin Dermatitis (sic) (1-10%)
(1984): Greenblatt DJ+, J Clin Psychiatry 45, 192 Diaphoresis (>10%) (1983): Kroboth PD+, Drug Intell Clin Pharm 17, 495
(1979): van der Kroef C, Lancet 2, 526 Exanthems Photosensitivity (1984): Hussar DA, Am Drug 190, 109 Pruritus (1983): Poeldinger W+, Neuropsychobiology 9, 135 (1981): Cobden I+, Postgrad Med J 57, 730 Purpura Rash (sic) (>10%) (1985): Jerram TC, Side Effects Drugs Annu 9, 39 Urticaria
Hair Hair-alopecia
Hair-hirsutism
Other Dysesthesia (<1%)
Dysgeusia (<1%) (1979): van der Kroef C, Lancet 2, 526 (1978): Fabre LF Jr+, J Clin Psychiatry 39, 679 Gingivitis Glossitis (<1%) Glossodynia (<1%) Headache Paresthesias (<1%) (1979): van der Kroef C, Lancet 2, 526 Sialopenia (>10%) (1995): Loesche WJ+, J Am Geriatr Soc 43, 401 Sialorrhea (1-10%) Stomatitis (<1%) Tinnitus Tremor (1-10%) Xerostomia (>10%) (1995): Loesche WJ+, J Am Geriatr Soc 43, 401 (1986): Hughes RRL+, Br J Clin Pract 40, 279 (1984): Greenblatt DJ+, J Clin Psychiatry 45, 192 (1983): Cohn JB, J Clin Psychiatry 44, 401
Trade names: Metahydrin (Aventis); Naqua (Schering)
Other common trade names: Anatran; Aquacot; Carvacron; Diurese; Doqua; Esmarin; Flute; Iopran; Niazide; Trichlon; Trichlorex
Indications: Edema, hypertension Category: Antihypertensive; Thiazide diuretic Half-life: N/A Clinically important, potentially hazardous interactions with: digoxin, lithium
Reactions
Skin Exanthems
Lichenoid eruption (<1%) Lupus erythematosus (1978): Pereyo-Torellas N, Arch Dermatol 114, 1097 Photosensitivity (<1%) Purpura (1962): Loftus LR+, JAMA 180, 410 Rash (sic) Urticaria Vasculltis (1962): Loftus LR+, JAMA 180, 410
Other Anaphylactoid reactions
Paresthesias Xerostomia *Note: Trichlormethiazide is a sulfonamide and can be absorbed systemically.
